Leuject

Cladribine, the active ingredient in Leuject, is a purine nucleoside analog presented as a subcutaneous injection for subcutaneous use. It is employed to treat certain hematologic malignancies and multiple sclerosis in adult patients.

GNH USA supplies Leuject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuject (cladribine) is used in diseases where abnormal lymphocyte proliferation is a key feature. - Hairy cell leukemia: induces remission by targeting malignant B‑cells. - Chronic lymphocytic leukemia: reduces disease burden through lymphocyte depletion. - Multiple sclerosis: decreases relapse frequency by modulating immune activity.

Cladribine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Lymphopenia: reduced lymphocyte counts. - Fatigue: persistent tiredness. - Nausea: mild to moderate stomach upset. - Fever: transient elevations in body temperature. - Headache: mild to moderate pain. - Injection site reactions: redness or swelling.

Serious or Rare Side Effects: - Severe infections: opportunistic or recurrent infections. - Autoimmune hemolytic anemia: destruction of red blood cells. - Secondary malignancies: emergence of new cancers. - Hepatic toxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Progressive multifocal leukoencephalopathy: rare brain infection.

Before initiating therapy with Leuject, several safety considerations should be observed. - Monitor blood counts: perform regular CBC to detect lymphopenia. - Assess infection risk: screen for active infections and vaccinate appropriately before treatment. - Evaluate renal function: adjust use in patients with impaired kidney function. - Avoid live vaccines: contraindicated during and after therapy until immune recovery. - Contraception: use effective birth control during treatment and for a defined period after. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent immunosuppressants: may amplify immunosuppression and infection risk. - Live vaccines: increase chance of vaccine‑derived disease. - Other purine analogues: additive toxicity to bone marrow.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., acyclovir): may require dose adjustment. - Antifungal agents (e.g., azoles): potential for altered metabolism. - Antihistamines: may mask early signs of allergic reactions. - Hepatotoxic drugs: monitor liver function tests.